Aspire Biopharma has agreed to acquire Dura Driver Control Systems, a global automotive supplier with more than $200 million in annual revenue, significantly reshaping the company’s revenue base and business mix.
Key Investor Takeaways
- Aspire Biopharma (NASDAQ:ASBP) has signed a definitive agreement to acquire Dura Driver Control Systems for $30 million in cash.
- The acquisition adds a business that generated more than $200 million in revenue and over $22 million in Adjusted EBITDA during 2025.
- The transaction dramatically diversifies Aspire beyond its pharmaceutical and drug-delivery technology operations.
- Dura brings a large intellectual property portfolio, including more than 310 patents and relationships with major automotive OEMs.
- Management stated it does not anticipate raising new equity financing to complete the acquisition.
Why ASBP Stock Is in Focus
The key development is Aspire Biopharma’s agreement to acquire 100% of Dura Driver Control Systems (DCS), a global manufacturer of automotive driver control technologies.
Under the terms of the agreement, Aspire will purchase DCS for $30 million in cash, with the acquired business becoming a wholly owned subsidiary. The transaction is expected to close during the third quarter of 2026, subject to customary closing conditions.
DCS operates 11 manufacturing facilities across North America, Europe, and Asia and serves more than 50 customers globally. The company supplies products used in vehicle electrification, safety systems, human-machine interfaces, mechatronic actuators, industrial cables, and control systems.
For fiscal 2025, DCS reported more than $200 million in revenue, more than $17 million in net income, and over $22 million in Adjusted EBITDA, according to unaudited figures provided by Aspire.
The business also brings a substantial intellectual property portfolio, including more than 310 patents and over 275 proprietary parts supporting more than 150 vehicle platforms worldwide.
Why This Matters for Investors
This acquisition represents a transformational shift for Aspire Biopharma.
Prior to the transaction, Aspire’s investment narrative centered largely on its patent-pending sublingual drug delivery technology and commercialization efforts around its pharmaceutical and nutraceutical products. The addition of DCS introduces a sizable operating business with established revenue, profitability, manufacturing infrastructure, and customer relationships.
For investors, the deal may significantly alter Aspire’s financial profile by adding immediate revenue generation, cash flow, and earnings from an operating company that is already commercially established.
The transaction also reduces Aspire’s reliance on the longer timelines and development risks often associated with emerging healthcare and biotechnology businesses. Management indicated that the stronger financial foundation could support continued development of its proprietary drug delivery technology while creating additional capital allocation flexibility.
At the same time, investors will likely evaluate how effectively management integrates a large automotive supplier into a company whose legacy operations are rooted in biotechnology. The acquisition introduces diversification, but it also creates a business model that spans two very different industries.
What to Watch Next
Investors will be watching several key developments:
- Completion of the acquisition during the third quarter of 2026.
- Details regarding the financing structure used to fund the $30 million purchase.
- Integration plans for DCS and its global manufacturing operations.
- Future guidance reflecting the combined company’s revenue and earnings profile.
- Whether Aspire provides updated capital allocation priorities following the transaction.
- Continued progress on Aspire’s proprietary drug delivery platform and caffeine product commercialization efforts.
The acquisition marks a major strategic pivot for Aspire, transforming it from a primarily biotechnology-focused company into a more diversified enterprise with substantial exposure to the global automotive supply chain.